Trademark: 87205265
Word
MYCOBIOME
Status
Dead
Status Code
602
Status Date
Monday, August 21, 2017
Serial Number
87205265
Mark Type
4000
Filing Date
Monday, October 17, 2016
Abandoned Date
Tuesday, July 25, 2017

Trademark Owner History

Classifications
5 Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; preparations in the nature of a vaginal probiotic for the treatment and/or prevention of bacterial or fungal vaginal infection; nutraceuticals for the treatment and/or prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and/or nutritional and dietary supplements; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplements, namely, probiotic compositions; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and/or bacterial probiotics, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome nutritional supplements, namely, probiotic compositions nutritional supplements, namely, probiotic compositions; fungus organisms for the treatment of the gastrointestinal tract; fungus organisms for the treatment of ulcerative colitis and crohn's disease; fungus organisms for the treatment of vaginal infection; providing information to others regarding the concept of the fungal community in the body

Trademark Events
Aug 21, 2017
Abandonment Notice Mailed - Failure To Respond
Aug 21, 2017
Abandonment - Failure To Respond Or Late Response
Jan 23, 2017
Notification Of Non-Final Action E-Mailed
Jan 23, 2017
Non-Final Action E-Mailed
Jan 23, 2017
Non-Final Action Written
Jan 13, 2017
Assigned To Examiner
Oct 20, 2016
New Application Office Supplied Data Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24